The largest database of trusted experimental protocols

Bms493

Manufactured by R&D Systems

BMS493 is a synthetic compound that functions as a retinoic acid receptor (RAR) antagonist. It inhibits the transcriptional activity of RARs, which are nuclear receptors that play a role in regulating gene expression.

Automatically generated - may contain errors

3 protocols using bms493

1

Induction of PGCLC from Dissociated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For PGCLC induction, cells were dissociated by incubation with Accutase and then transferred into a low-cell-binding U-bottom 96-well plate (Greiner, #650970) in GK15 medium (GMEM (Thermo, #11017035) containing 15% KSR, 0.1 mM NEAA, 1 mM sodium pyruvate (Thermo, #11360070), 2 mM GlutaMax, 0.1 mM 2-mercaptoethanol, and 1 × penicillin/streptomycin) supplemented with 200 ng/ml human BMP4 (R&D Systems, #314-BP-01 M), 100 ng/ml mouse SCF (R&D Systems, #455-MC-500), 1000 U/ml human LIF (Wako, #125-06661), 50 ng/ml human EGF (R&D Systems, #236-EG) and 10 μM ROCK inhibitor with or without 2.5 μM IWR1 (TOCRIS, #3532) and 1.0 µM BMS493 (R&D Systems, #3509/10). In each well, 5 × 103 cells were used. In the experiments requiring enforced expression of the transgenes, 100 μM dexamethasone, 0.5 μg/ml doxycycline, and 0.5 μM Shield-1, which induce SOX17, BLIMP1, and TFAP2C expression, respectively, were added to the medium11 (link). To enforce the expression of SOX17 alone, only 100 μM dexamethasone was added.
+ Open protocol
+ Expand
2

Modulating Metabolic Pathways in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To block RA signaling, a total of 220 mg of the pan RA receptor inverse agonist BMS 493 (R&D Systems; RAi) was resuspended in 30 µl of biotechnology performance–certified DMSO (Sigma-Aldrich) and administered intraperitoneally to C57BL/6 WT mice every day for 8 d as previously described (Kastner et al., 2001 (link)). To block FAO, mice were administered 15 mg/kg etomoxir (Tocris Bioscience) every other day throughout the course of infection or for 7 d under steady-state conditions. To block glycolysis, mice were administered 1 g/kg 2-DG (Cayman Chemicals) every other day starting upon infection with T. muris for 7 d and then every day thereafter. For simultaneous treatment, mice were treated with the indicated combination in a total volume of 30 µl DMSO or DMSO only as a vehicle control. To block FA uptake, mice were treated with 200 mg/kg orlistat every other day starting 7 d after infection. Control mice received DMSO only.
+ Open protocol
+ Expand
3

IL-33 Induced ILC2 Activation and Expansion

Check if the same lab product or an alternative is used in the 5 most similar protocols
For ILC2 activation and expansion, mice received injections of 200 or 400 ng recombinant mouse (rm) IL-33 (BioLegend) in 200 μl PBS i.p. on four consecutive days. Controls received 200 μl PBS. ILC2s were isolated at 2–3 wk after the first IL-33 injection. To block RA signaling, a pan-RAi (BMS493; R&D) was dissolved in DMSO (final conc. 29.3 µg/μl). 220 µg RAi/animal (diluted in PBS) was administered i.p. every second day. The same DMSO concentration was administered to control animals.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!